Wyatt said that although UK bodies such as the NHS and watchdog NICE describe the treatment as experimental, about 80% of people who had the treatment responded to some degree and more than 50% saw the progression of their MS halted. The charity the MS Society says the treatment could have long-term benefits for some people with MS but that larger studies are needed to better understand the impact of this aggressive treatment compared with existing therapies.

Click here to view.

Click here to view Lancet paper (June 2016).